- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.03. | FDA approves IND application for Everest's cancer vaccine | ||
| 24.03. | AstraZeneca to invest $2.5bn in R&D centre in China | ||
| 21.03. | China conditionally approves Hutchmed's Tazverik for follicular lymphoma | ||
| 21.03. | European agencies catch up with speedier regulatory pathways for CGTs in the US | ||
| 21.03. | Global funding cuts reversing decades of tuberculosis progress, WHO says | ||
| 21.03. | How to manage regulatory complexities with clinical trial data | ||
| 21.03. | Menarini to enhance BPDCN detection with VisualDx's link | ||
| 21.03. | FDA approves Johnson & Johnson's Tremfya to treat Crohn's disease | ||
| 20.03. | Servier and Black Diamond sign deal for solid tumours therapy | ||
| 20.03. | International Reference Pricing (IRP) 2024: A year in review | ||
| 20.03. | Roche's discontinued Alzheimer's drug shows signs of preventing onset | ||
| 20.03. | Pfizer sells 7.3% stake in Haleon for $3.3bn | ||
| 20.03. | Oxford BioTherapeutics and Roche link on antibody cancer treatments | ||
| 20.03. | Blood cancers dominate CAR-T pipeline | ||
| 19.03. | USPTO allows patents for Remedy's large hemispheric infarction drug | ||
| 19.03. | Sacklers to pay up to $7bn in Purdue Pharma's opioid settlement plan | ||
| 19.03. | Insight and insitro partner on AI model to seek ocular biomarkers | ||
| 19.03. | Arbor to advance gene editing treatments with $73.9m funding | ||
| 18.03. | Opko and Entera focus on oral care for obesity and metabolic disorders | ||
| 18.03. | Curevo procures $110m and former-GSK exec for shingles vaccine candidate | ||
| 18.03. | Health Canada approves Biogen's Skyclarys for Friedreich's ataxia | ||
| 18.03. | Big tech meets biotech: Recursion and the AI gold rush in pharma | ||
| 18.03. | AstraZeneca and Alteogen agree on ALT-B4 platform tech | ||
| 17.03. | Investigating key strategies for optimising clinical trial supply chains in 2025 | ||
| 17.03. | Incyte stock hit 11% despite paediatric dermatology trials hitting target |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
